CoreValve, S.A. Release: First Percutaneous Aortic Valve Replacement (PAVR) Procedure Without Any Cardiac Support

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve ( announced today that its patented ReValving System, consisting of a breakthrough 18-French-sized delivery catheter, was used to percutaneously implant its proprietary porcine pericardial tissue bioprostheses over the severely calcified aortic heart valves of an 88-year-old female patient and a 77-year-old male patient—without the use of extracorporeal bypass, other cardiac assistance or even rapid pacing. These first-ever medical-milestone procedures took routine interventional times to complete, and the patients were released from the ICU within hours of the completion of the ReValving procedure and are awaiting discharge from the hospital.

Back to news